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Objective: To analyze the characteristics of patients who needed a blood transfusion due to epistaxis-caused
anemia and to define potential risk factors.
Design: Retrospective cohort study.
Setting: A total cohort of 591 epistaxis patients, prospectively included between March 2007 and April 2008 at the
ENT department of the University Hospital of Zurich, was evaluated concerning the need for blood transfusions.
Methods: The clinical charts and medical histories of these patients were evaluated.
Main outcome measures: Common parameters that increase the risk for severe anemia due to epistaxis.
Results: Twenty-two patients required blood transfusions due to their medical condition. 22.7% suffered from
traumatic nosebleeds. Another 27.3% had a known medical condition with an increased bleeding tendency. These
proportions were significantly higher than in the group of patients without need of blood transfusion. The odds
ratio for receiving a blood transfusion was 14.0 in patients with hematologic disorders, 4.3 in traumatic epistaxis
and 7.7 in posterior bleeders. The transfusion-dependent epistaxis patients suffered significantly more often from
severe posterior nosebleeds with the need for a surgical therapeutic approach.
Conclusions: Patients with severe nosebleeds either from the posterior part of the nose or with known
hematologic disorders or traumatic epistaxis should be closely monitored by blood parameter analyses to evaluate
the indication for hemotransfusion. The acronym THREAT (Trauma, Hematologic disorder, and REAr origin of
bleeding → Transfusion) helps to remember and identify the factors associated with an increased risk of receiving
blood transfusion.
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Epistaxis is the most common emergency in rhinology
and accounts for almost six hundred consultations at
the University Hospital of Zurich per year [1]. Most
commonly the bleeding originates from the anterior part
of the nose and can easily be controlled by chemical or
electrical cautery or anterior packing. On the other hand,
epistaxis can also be severe, requiring hospitalization
and “aggressive” management including repeated nasal
packing, surgery or arterial embolization [2-4]. Severe
epistaxis is usually posterior in origin. Some patients even
require blood transfusions due to their high level of blood* Correspondence: michael.soyka@usz.ch
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reproduction in any medium, provided the orloss. A predominantly benign disorder can therefore also
become life-threatening. Blood transfusions must be
considered if hemoglobin levels around 7 g/dl are present.
If normovolemia cannot be maintained, the patient is
critically ill or the patient has other co-morbidities (e.g.
cardiovascular and chronic pulmonary disease, receiving
chemotherapy etc.) a blood transfusion has to be con-
sidered earlier and despite higher hemoglobin levels [5-7].
Epistaxis may be posttraumatic, iatrogenic (after endo-
nasal surgery) or “spontaneous”. Numerous causative
factors such as local nasal inflammation, medication, plate-
let and coagulation abnormalities, alcoholism and heredi-
tary hemorrhagic telangiectasia have been suggested [8].
For a long time, hypertension was considered to be a major
cause of spontaneous epistaxis, however this topic appears
to be more controversial in recent literature [9-13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the small population of patients who needed blood
transfusions during their epistaxis treatment and to
search for common factors that may represent risk
factors. For this reason a retrospective analysis of a large
study population was conducted. To our knowledge this
is the first report of this topic in the literature.
Methods
Patients
Patients presenting at the ENT department of the Uni-
versity Hospital of Zurich for the reason of epistaxis
were prospectively included in a previous study [1] be-
tween March 2007 and April 2008. As the original
prospectively recorded data contained information on
systemic disorders and the need for blood transfusion, it
was possible to further investigate those patients. We
therefore retrospectively analyzed the data with particu-
lar interest in patients who required blood transfusions.
All patients were divided into two groups: those requir-
ing a blood transfusion during their epistaxis treatment
and those who did not receive any blood-products. Mul-
tiple factors influence the decision of giving blood to a
patient during the treatment of epistaxis. In our clinic
the administration of blood transfusions is evaluated
with respect to the patients’ hemoglobin levels, sym-
ptoms (low blood pressure, tachycardia, dizziness) and
medical co-morbidities such as a high risk for cardiac
infarction. As this study was conducted retrospectively
we did not define clear cut-off values or conditions for
the need of hemotransfusion. The criteria are further
reviewed in the discussion section.
The lowest hemoglobin level before transfusion, site of
bleeding, history of hematologic or vascular disorder,
history of acute nose trauma, exposure to anticoagulants
and blood platelet antiaggregant medications as well as
the type of treatment were evaluated for their associ-
ation with the need for blood transfusions. Patients were
asked about their history of hypertension to find a pos-
sible link to an increased risk of blood transfusion. All
patients who confirmed suffering from arterial hyperten-
sion were taken into the “positive hypertension-history”
group even if blood pressure was well-adjusted with
medication at the moment of presentation.
Patients with epistaxis due to trauma with relevant
blood loss from additional sites of the body, other than
the nose itself, were excluded. A nose trauma was
defined as a direct or indirect injury of nasal/paranasal
structures with a consecutive nosebleed, visible bruise
marks, scars or nasal bone fracture at presentation. Nose
picking was not considered a nasal trauma, as its rele-
vance in epistaxis remains questionable [14].
Posterior bleeding was defined as a bleeding source
not visible upon anterior rhinoscopy.The treatment plan at our department has previously
been published [1] and evaluated [15]. In summary, the
treatment of choice for anteriorly located bleeding is
electric or chemical cautery. For posterior epistaxis a
nasal endoscopy is performed in surface anesthesia to
localize and if possible cauterize a bleeding source. As
this is rarely possible we usually place an inflatable
Rapid RhinoW packing (7.5 cm anterior-posterior, ENT
Arthrocare Europe, Stockholm, Sweden) in posterior
bleeds. If this treatment fails we insert a Foley balloon
catheter and pack the nose with fat-gauze. In case of
repeated failure or if a new bleed arises after removing of
the packing, a rigid nasal endoscopy is performed in general
anesthesia and all branches of the sphenopalatine artery are
coagulated and transected. If the bleeding persists or the
source of bleeding is clearly located in the supply area of
the ethmoidal arteries, external closure is performed by
lynch incision or transcaruncular approach [16].
Ethical consideration
Data collection was performed with the permission of
the local ethical committee and review board.
Statistical analysis
Comparisons between the groups were performed with a
Chi-Square test for categorical variables. For the multi-
variate analysis a logistic regression model using a step-
wise backward method was calculated using R [17]
(version 2.14.1). The explanatory variables bleeding
localization (anterior/posterior), trauma (yes/no), exposure
to anticoagulants or platelet antiaggregants (yes/no), his-
tory of hypertension (yes/no) and history of hematologic
or vascular disorder (yes/no) were included in the full
model. The 5% significance level was applied as a thresh-
old for exclusion of explanatory variables from the model
and for other statistical tests. Apart from the regression
analysis, all other statistical computations were performed
using Prism Version 5 (GraphPad Software, USA).
Results
Between March 2007 and April 2008, 591 individuals
were seen at the ENT department of the University Hos-
pital of Zurich for the reason of epistaxis. In the litera-
ture this is one of the largest epistaxis populations that
have been investigated.
Twenty-two patients (3.7%) needed blood transfusion
due to their medical condition. Table 1 shows the
characteristics of these 22 patients in comparison to the
group of epistaxis patients without blood transfusions.
Table 2 indicates hemoglobin values and number of blood
transfusions in this small patient group. Age and gen-
der distribution was equal in both groups. 72.7% of the
blood transfusion group presented with posterior
epistaxis. This percentage is significantly higher than
Table 1 Patients characteristics
Blood transfusion
Yes, n = 22, 3.7%
Blood transfusion
No, n = 569, 96.3%
p
Variable Value Number % Number %
Sex male 11 50 320 56.2 0.7
female 11 50 249 43.8
Bleeding Localization anterior 5 22.7 402 70.7 <0.01
posterior 17 77.3 167 29.3
Trauma Yes 5 22.7 30 5.3 <0.01
No 17 77.3 539 94.7
Platelet antiaggregant medications Yes 9 40.9 207 36.4 0.7
No 13 59.1 362 63.6
Oral anticoagulants Yes 2 9.1 114 20 0.3
No 20 90.9 455 80
History of hypertension Yes 12 54.5 317 55.7 1
No 10 45.5 242 42.5
Known hematologic and vascular disorders Yes 6 27.3 19 3.3 <0.01
No 16 72.7 550 96.7
Elevated liver enzymes Yes 5 22.7 98 17.2 0.6
No 17 77.3 471 82.8
Therapy (>1 modality per patient possible) electric or chemical cautery 7 31.8 483 84.9 <0.01
Nasal packing 14 63.6 197 34.6 0.01
Operation 7 31.8 31 5.5 <0.01
First bleeding episode at presentation Yes 5 22.7 176 30.9 0.5
No 17 77.3 393 69.1
Hospitalisation Yes 19 86.4 80 14.1 <0.01
No 3 13.6 489 85.9
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therefore the treating modalities where also signifi-
cantly different. Surgical management of epistaxis with
endoscopic closure of the sphenopalatine artery or
open ligature of the ethmoidal arteries was needed in
31.8% of patients in the blood transfusion group,
whereas in patients without blood transfusions only
5.5% had a surgical intervention (p < 0.01). Only 5
patients (0.85%) received open ligature of the eth-
moidal arteries. One of these 5 required blood
transfusion.
A multivariate analysis including the variables “loca-
lization of the bleeding, trauma, antiaggregational me-
dication, anticoagulants, history of hypertension andTable 2 Transfusion related characteristics of patients
Variable Value
Age years
Blood Transfusions Number of units
Hemoglobin level before Transfusion g/lhematologic or vascular disorders” revealed an increased
risk for the administration of hemotransfusions. In the final
model a significantly increased risk for hemotransfusions
was found for posterior bleedings (p < 0.01) with an odds
ratio (OR) of 7.7 (95%-CI 2.8/24.7), hematologic or vascular
disorders (p < 0.01) with an OR of 14.0 (95%-CI 4.1/45.7)
and trauma (p = 0.02) with an OR of 4.3 (95%-CI 1.2/45.7).
Doing a subgroup analysis on patients who were on
antiaggregational medication only the localization of the
bleeding remained in the model. A significantly higher pro-
portion of posterior epistaxis (p < 0.01) was found showing
an OR of 26.3 (95%-CI 4.9/485.9). Subgroup regression
analyses within the group of posterior bleeders revealed an
increased risk of blood transfusions when hematologicBlood transfusion
Yes, n = 22, 3.7%
Blood transfusion
No, n = 569, 96.3%
Range Median Range Median
20-95 72 12-97 69.5
1-6 2 - -
48-95 73.5 - -
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increased risk in trauma patients OR 3.2 (p = 0.07).
Of the 22 patients in the blood transfusion group, 6
patients (27.3%) suffered from hematologic or vascular
disorders, namely: hereditary hemorrhagic telangiectasia
(Osler-Weber-Rendu disease), recurrent thrombocytopenia
of unknown etiology, myelodysplastic syndrome, non-
hodgkin lymphoma, splenomegaly with thrombocytopenia
due to non-hodgkin lymphoma and multiple myeloma.
Three patients (13.6%) suffered from other severe medical
preconditions, 6 (27.3%) had recurrent nosebleeds requir-
ing several interventions. Only 2 (9%) had no special risk
factors besides taking anticoagulants or antiaggregational
medication. Taking together all patients with either trau-
matic epistaxis or hematologic/systemic medical disorders
we found a sensitivity of 64% and a specificity of 84% when
testing for transfusion requirement, with a negative
predictive value of 98%.
Patients in the blood transfusion group had a similar
exposure to anticoagulants and platelet antiaggregant
medications as patients without transfusions. A correl-
ation between the intake of these medications and the
need of a blood transfusion could not be shown. There
was also no difference in the appearance of elevated liver
enzymes between the two groups. A known history of
hypertension was present in approximately half of the
patients in both groups.
The 22 patients with a need for blood transfusions
received on average 2.6 units per patient (range 1–6,
median 2). The lowest hemoglobin value measured be-
fore transfusion ranged between 48 and 95 g/l (median
73.5 g/l).
The hospitalization rate was 16.8% in the study popu-
lation with 99 patients spending at least one night in
hospital. In the blood transfusion group this rate was
significantly higher (p < 0.01) with 86.4% of patients
hospitalized staying one night or longer. In the subgroup
of hospitalized patients regression analysis showed an
increased risk just for patients with hematologic
disorders with an OR of 6.8 (p = 0.02). Concerning
complications, one patient in the transfusion group
suffered from myocardial infarction and had to be trans-
ferred to the intensive care unit. None of the patients in
either group died as a consequence of epistaxis or its
treatment.
Discussion
In most cases epistaxis is a benign condition, but some-
times it can be serious and become a challenging med-
ical problem in otorhinolaryngology. Some patients with
severe epistaxis, usually posterior in origin, required
more intensive care. Ninety-nine patients (16.8%) out of
our collective of 591 needed a hospitalization. The need
for blood transfusion occurred in 22 (3.7%) patients.These 22 patients had some common characteristics. As
this study was performed retrospectively we need to be
aware of the potential report-bias, where doctors keep
better records of “difficult” patients (such as those
addressed by this study) than in unproblematic cases.
We tried to reduce this bias by including a large number
of patients and using the prospective protocol in which
data was collected.
Most (77.3%) of the patients in the transfusion group
suffered from posterior epistaxis. Posterior localization
of bleeding is a predictor of surgical treatment a strong
association has been shown between surgery for epi-
staxis and the need for blood transfusions [18]. Another
study reported similar rates of blood transfusion (45.5%)
in patients requiring sphenopalatine artery ligation [19].
However this investigation only included 11 patients and
the criteria for blood transfusion were not described.
Transfusion strategy
In our collective, of the subset of patients that required
surgical treatment, only 18.4% received blood trans-
fusions. In accordance with current literature, we follow
a restrictive transfusion strategy at our institution.
The mean transfusion trigger in our patients was a
hemoglobin level of 7.4 g/dl. For many years physicians
believed that a hemoglobin of 10 g/dl and a hematocrit
of 30% represented the goal in anemic patients, espe-
cially those undergoing surgery and those with cardiac
disease [20]. In the last decade many studies have
demonstrated that a substantially lower hemoglobin
level (7 g/dl) can be tolerated in patients who are not
critically ill, if normovolemia is maintained [5-7]. We
also considered blood transfusion if there was an acute
severe nosebleed with signs of hypovolemia, identified
by tachycardia and low blood pressure or in high-risk
patients (e.g. cardiovascular and chronic pulmonary
disease, patients receiving chemotherapy etc.) with
hemoglobin levels below 9 g/dl. We follow this restrict-
ive transfusion regime because besides the benefits of a
blood transfusion, it can also be life threatening and is
believed to exert serious adverse effects (e.g. lengthened
hospital stay and impaired recovery) [21,22].
Transfusion group characteristics
The risk of receiving blood products increases sevenfold
in patients with posterior bleedings compared to anterior
epistaxis. In those receiving antiaggregational medication
this risk is further increased to an odds ratio of 26. As
shown by multivariate subgroup analysis, only posterior
localization of the bleeding source increased the necessity
to administer transfusions to patients on acetylsalicylic
medication or taking Clopidogrel significantly.
Non-iatrogenic posttraumatic epistaxis was significantly
more frequent in the transfusion group with a larger than
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jury of a vessel is suspected to be worse than in cases of
spontaneous epistaxis. It can be assumed that in traumatic
cases spontaneous closure is more difficult and therefore
prolonged bleeding with increased blood loss can be
expected. As mentioned before we excluded patients with
relevant blood loss from additional trauma sites of the
body.
Six patients in the transfusion group suffered from
hematologic or vascular disorders that are known to have
an influence on hemostasis or vessel integrity. These
patients have a 14 times higher risk for hemotransfusion.
Hereditary hemorrhagic telangiectasia (Osler-Weber-
Rendu disease) is an autosomal dominant disorder
characterized by abnormal angiogenesis. The most com-
mon manifestation is epistaxis resulting from trauma
to thin-walled telangiectasias [23]. Myelodysplastic
syndrome is a disorder of hematopoietic stem cells
characterized by ineffective hematopoiesis. The result is
pancytopenia leading to anemia and an increased risk of
infection or bleeding [24]. In multiple myeloma abnor-
mal hemostasis, specifically the imbalance in function of
all major components of the coagulation cascade is
known [25]. In non-Hodgkin's lymphomas autoimmune
thrombocytopenia is a common immune-hematologic
complication [26].
Another 3 patients in the transfusion group who had
no trauma and no known vascular or hematologic dis-
ease were found to have other major medical problems.
One patient suffered from alcohol-induced myocardial
pathology, another from primary biliary cirrhosis and
was immunosuppressed after kidney transplantation
and the third had an HIV infection with microcytic
hypochromic anemia. Six other patients who needed
blood transfusion had multiple treatments with treat-
ment failure in the weeks before presenting at our insti-
tution. Only 2 patients who received a blood transfusion
had no such risk factors besides Aspirin and Clopidogrel
intake.
As the cohort of our epistaxis patients consists of a
very heterogeneous collection of patients one could of
course argue that risk factors could be better determined
in subgroup analyses. However it was not the aim of the
study to subdivide the population but much rather to
give treating doctors hints on when to be cautious and
to be alert of potential complications due to high blood
loss. Nevertheless we performed multiple binary logistic
regression analyses in the subgroups of posterior blee-
ders and also in the hospitalized subgroup. In posterior
epistaxis patients the risk factors remained the same,
being trauma and hematologic disorders. In the hos-
pitalized patients only hematologic disorders stayed in
the model and no other risk factors could be identified,
which is not surprising. Hospitalization is reverselylinked with transfusions as most of the patients stayed in
hospital after the administration of blood products,
therefore testing in this highly biased subgroup does not
yield relevant new information.
Synopsis of key findings
Based on our results we suggest monitoring all patients
with either traumatic epistaxis or known medical and
hematologic disorders more closely than others. Taking
these parameters into account 64% of all at risk patients
will be identified. Including recurrences will increase this
number to 91% at the expense of specificity. We are fully
aware that the above mentioned risk factors alone will
not identify all patients with the need of a transfusion,
they however will help clinicians in the decision of
whether or not to perform blood testing in questionable
situations. There is no substitute for a thorough risk
analysis of every individual patient.
Conclusions
We identified 3 major risk indicators for the need of
blood transfusions in our epistaxis cohort, being:
Traumatic bleeding, posterior origin of bleeding source
and hematologic/vascular disorders. The acronym
THREAT (Trauma, Hematologic disorder, and REAr
origin of bleeding → Transfusion) helps to remember
and identify those risk factors. Patients with severe
nosebleeds, especially of posterior origin, who had sev-
eral bleeding episodes over the time before presenting
at our institution, were at increased risk to undergo sur-
gery and also to receive blood transfusions. Our investi-
gation also showed that patients who are known to have
hematologic, vascular or other systemic disorders and
patients with nosebleeds after trauma should be closely
monitored including blood parameter analyses.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KM performed the data collection and wrote the manuscript, NA collected
the data and critically reviewed the manuscript, BAR performed statistical
analyses, DH critically reviewed the study plan and helped in writing the
text, MBS has planned the study, helped with data collection and reviewed
the manuscript. All authors read and approved the final manuscript.
Acknowledgment
We would like to thank Nicole van Veelen, MD for her thorough correction
of the manuscript.
This material has never been published and is not currently under evaluation
in any other peer-reviewed publication.
Author details
1Department of Otorhinolaryngology, Head and Neck Surgery, Kantonsspital
St. Gallen, St. Gallen, Switzerland. 2Department of Otorhinolaryngology, Head
and Neck Surgery, University Hospital Zurich, Zurich 8091, Switzerland. 3Swiss
Federal Veterinary Office, Zollikofen, Switzerland.
Received: 19 November 2012 Accepted: 25 December 2012
Published: 31 January 2013
Murer et al. Journal of Otolaryngology - Head and Neck Surgery 2013, 42:4 Page 6 of 6
http://www.journalotohns.com/content/42/1/4References
1. Soyka MB, Rufibach K, Huber A, et al: Is severe epistaxis associated with
acetylsalicylic acid intake? Laryngoscope 2010, 120(1):200–207.
2. Klossek JM, Dufour X, de Montreuil CB, et al: Epistaxis and its
management: an observational pilot study carried out in 23 hospital
centres in France. Rhinology 2006, 44(2):151–155.
3. Pollice PA, Yoder MG: Epistaxis: a retrospective review of hospitalized
patients. Otolaryngology–head and neck surgery: official journal of American
Academy of Otolaryngology-Head and Neck Surgery 1997, 117(1):49–53.
4. Douglas R, Wormald PJ: Update on epistaxis. Curr Opin Otolaryngol Head
Neck Surg 2007, 15(3):180–183.
5. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized,
controlled clinical trial of transfusion requirements in critical care.
Transfusion requirements in critical care investigators, Canadian Critical
Care Trials Group. N Engl J Med 1999, 340(6):409–417.
6. Marshall JC: Transfusion trigger: when to transfuse? Crit Care 2004,
8(Suppl 2):S31–33.
7. Carless PA, Henry DA, Carson JL, et al: Transfusion thresholds and other
strategies for guiding allogeneic red blood cell transfusion.
Cochrane Database Syst Rev 2010, 6(10):CD002042.
8. Folz BJ, Kanne M, Werner JA: Current aspects in epistaxis. HNO 2008,
56(11):1157–1165. quiz 1166.
9. Fuchs FD, Moreira LB, Pires CP, et al: Absence of association between
hypertension and epistaxis: a population-based study. Blood Press 2003,
12(3):145–148.
10. Lubianca Neto JF, Fuchs FD, Facco SR, et al: Is epistaxis evidence of
end-organ damage in patients with hypertension? Laryngoscope 1999,
109(7 Pt 1):1111–1115.
11. Knopfholz J, Lima-Junior E, Precoma-Neto D, et al: Association between
epistaxis and hypertension: a one year follow-up after an index episode
of nose bleeding in hypertensive patients. Int J Cardiol 2009,
134(3):e107–109.
12. Celik T, Iyisoy A, Yuksel UC, et al: A new evidence of end-organ damage in
the patients with arterial hypertension: epistaxis? Int J Cardiol 2010,
141(1):105–107.
13. Page C, Biet A, Liabeuf S, et al: Serious spontaneous epistaxis and
hypertension in hospitalized patients. Eur Arch Otorhinolaryngol 2011,
268(12):1749–53.
14. Joice P, Ross P, Robertson G, et al: The effect of hand dominance on
recurrent idiopathic paediatric epistaxis. Clin Otolaryngol 2008,
33(6):570–574.
15. Soyka MB, Nikolaou G, Rufibach K, et al: On the effectiveness of treatment
options in epistaxis: an analysis of 678 interventions. Rhinology 2011,
49(4):474–478.
16. Morera E, Artigas C, Ferran L, et al: Transcaruncular electrocoagulation of
anterior ethmoidal artery for the treatment of severe epistaxis.
Laryngoscope 2011, 121(2):446–450.
17. R Development Core Team: A language and environment for statistical
computing. R Foundation for Statistical Computing; Vienna, Austria 2008.
18. Barlow DW, Deleyiannis WB, Pinczower EF: Effectiveness of surgical
management of epistaxis at a tertiary care center. Laryngoscope 1997,
107(1):21–24.
19. Voegels RL, Thome DC, Iturralde PP, et al: Endoscopic ligature of the
sphenopalatine artery for severe posterior epistaxis. Otolaryngology–head
and neck surgery: official journal of American Academy of Otolaryngology-
Head and Neck Surgery 2001, 124(4):464–467.
20. McFarland JG: Perioperative blood transfusions: indications and options.
Chest 1999, 115(5 Suppl):113S–121S.
21. Vamvakas EC, Blajchman MA: Blood still kills: six strategies to further
reduce allogeneic blood transfusion-related mortality. Transfus Med Rev
2010, 24(2):77–124.
22. Carson JL, Hill S, Carless P, et al: Transfusion triggers: a systematic review
of the literature. Transfus Med Rev 2002, 16(3):187–199.
23. Guttmacher AE, Marchuk DA, White RI Jr: Hereditary hemorrhagic
telangiectasia. N Engl J Med 1995, 333(14):918–924.
24. Larson RA: Myelodysplasia: when to treat and how. Best Pract Res Clin
Haematol 2006, 19(2):293–300.25. Coppola A, Tufano A, Di Capua M, et al: Bleeding and thrombosis in
multiple myeloma and related plasma cell disorders. Semin Thromb
Hemost 2011, 37(8):929–945.
26. Hauswirth AW, Skrabs C, Schutzinger C, et al: Autoimmune
thrombocytopenia in non-Hodgkin's lymphomas. Haematologica 2008,
93(3):447–450.
doi:10.1186/1916-0216-42-4
Cite this article as: Murer et al.: THREAT helps to identify epistaxis
patients requiring blood transfusions. Journal of Otolaryngology - Head
and Neck Surgery 2013 42:4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
